Share on StockTwits

Abbott Laboratories (NYSE:ABT) is scheduled to be releasing its Q114 earnings data on Wednesday, April 16th. Analysts expect Abbott Laboratories to post earnings of $0.36 per share and revenue of $5.29 billion for the quarter. Abbott Laboratories has set its FY14 guidance at 2.21-2.26 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Abbott Laboratories (NYSE:ABT) last released its earnings data on Wednesday, January 22nd. The company reported $0.58 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.58. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the prior year, the company posted $1.51 earnings per share. The company’s quarterly revenue was up .4% on a year-over-year basis. On average, analysts expect Abbott Laboratories to post $2.20 EPS for the current fiscal year and $2.47 EPS for the next fiscal year.

Abbott Laboratories (NYSE:ABT) opened at 37.74 on Tuesday. Abbott Laboratories has a 1-year low of $32.70 and a 1-year high of $40.49. The stock has a 50-day moving average of $38.8 and a 200-day moving average of $37.6. The company has a market cap of $58.235 billion and a price-to-earnings ratio of 22.81. Abbott Laboratories also was the recipient of a significant decline in short interest in the month of January. As of March 31st, there was short interest totalling 12,603,745 shares, a decline of 25.8% from the March 14th total of 16,981,772 shares. Based on an average trading volume of 9,290,714 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.8% of the company’s shares are sold short.

Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Abbott Laboratories in a research note on Monday. They now have a $46.00 price target on the stock. On a related note, analysts at Zacks reiterated a “neutral” rating on shares of Abbott Laboratories in a research note on Friday, March 21st. They now have a $41.00 price target on the stock. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $38.78.

Abbott Laboratories (NYSE:ABT) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.